Risperidone and Haloperidol Comparative Effects of Positive Symptoms Patient Schizophrenic
Abstract
Several studies have made a sub category of the symptoms of schizophrenia into five parts: positive symptoms, negative symptoms, cognitive symptoms, symptoms of aggressive and depressive / anxious. Some studies also indicate that risperidone is a preparation that has high efficacy for positive symptoms of schizophrenia and negative symptoms of schizophrenia also improve better than conventional antipsychotics.mThis study was an experimental study in the form of two-group pretest-posttest design with consecutive sampling performed 40 schizophrenic patients who came for treatment to psychiatry inpatient and outpatient BLUD RSJ Propsu period March 1, 2010 - August 31, 2010. Patients with schizophrenia who met the inclusion criteria and underwent total PANSS positive symptoms before treatment therapy 20 samples will be treated with risperidone and 20 samples treated with haloperidol then were followed up every week until the fourth week of the inspection and the total PANSS positive symptoms. From a statistical test to test for independent samples in total PANSS score of zero to weeks and weeks to four PANSS total score differences were found on average to risperidone treatment group 50.2 (SD ± 9.7) and the difference in the PANSS total score average for haloperidol treatment group of 47.4 (SD ± 6.5), P = 0.281. No difference in total PANSS score based group intervention. From test to test for independent samples positive PANSS scores week to zero and week four PANSS positive score differences were found on average to risperidone therapy of 13.1 (SD ± 3.4) and the difference in PANSS positive scores on average for group therapy haloperidol was 10.5 (SD ± 1.9) P = 0.005. There are differences in symptom positive delta based group intervention. In this study risperidone group showed no significant differences in symptom score of the PANSS positive until the fourth week compared with the use of haloperidol group.
Keywords: schizophrenic patients, risperidone, haloperidol, PANSS, positive symptoms.
To list your conference here. Please contact the administrator of this platform.
Paper submission email: JBAH@iiste.org
ISSN (Paper)2224-3208 ISSN (Online)2225-093X
Please add our address "contact@iiste.org" into your email contact list.
This journal follows ISO 9001 management standard and licensed under a Creative Commons Attribution 3.0 License.
Copyright © www.iiste.org